Fosamprenavir: drug development for adherence (Q36498882)

14 August 2017

1 reference

title

Fosamprenavir: drug development for adherence (English)

1 reference

14 August 2017

E Kelly Hester

1

1 reference

14 August 2017

Haley V Chandler

series ordinal

2

1 reference

14 August 2017

Kelli M Sims

series ordinal

3

1 reference

14 August 2017

language of work or name

English

0 references

publication date

6 June 2006

1 reference

Annals of Pharmacotherapy

14 August 2017

published in

1 reference

14 August 2017

volume

40

1 reference

14 August 2017

issue

7-8

1 reference

14 August 2017

page(s)

1301-1310

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

14 August 2017

cites work

1 reference

Paradoxes of adherence and drug resistance to HIV antiretroviral therapy

21 January 2018

1 reference

Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance

21 January 2018

1 reference

Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?

21 January 2018

1 reference

Adherence to HAART Regimens

21 January 2018

1 reference

Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers

21 January 2018

1 reference

Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients

21 January 2018

1 reference

The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients

21 January 2018

1 reference

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

21 January 2018

1 reference

Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase n

21 January 2018

1 reference

Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors

21 January 2018

1 reference

GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks

21 January 2018

1 reference

Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors

21 January 2018

1 reference

Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.

21 January 2018

1 reference

Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers

21 January 2018

1 reference

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients

21 January 2018

1 reference

Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus

21 January 2018

1 reference

Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients

21 January 2018

1 reference

The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials

21 January 2018

1 reference

Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence.

21 January 2018

1 reference

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1G034

1 reference

14 August 2017

1 reference